Cargando…
Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment
BACKGROUND: Multidrug resistance (MDR) has emerged to be a major hindrance in cancer therapy, which contributes to the reduced sensitivity of cancer cells toward chemotherapeutic drugs mainly owing to the over-expression of drug efflux transporters. The combination of gene therapy and chemotherapy h...
Autores principales: | Liang, Xiao, Wang, Yudi, Shi, Hui, Dong, Mengmeng, Han, Haobo, Li, Quanshun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019667/ https://www.ncbi.nlm.nih.gov/pubmed/33833512 http://dx.doi.org/10.2147/IJN.S304526 |
Ejemplares similares
-
Insights into the binding mode of AS1411 aptamer to nucleolin
por: Bie, Lihua, et al.
Publicado: (2022) -
Anti-nucleolin aptamer AS1411: an advancing therapeutic
por: Van den Avont, Alexander, et al.
Publicado: (2023) -
AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation
por: Iturriaga-Goyon, Emilio, et al.
Publicado: (2021) -
Locking up the AS1411 Aptamer with a Flanking Duplex: Towards an Improved Nucleolin-Targeting
por: Miranda, André, et al.
Publicado: (2021) -
Targeted delivery of doxorubicin and therapeutic FOXM1 aptamer to tumor cells using gold nanoparticles modified with AS1411 and ATP aptamers
por: Abdollahzade, Aref, et al.
Publicado: (2023)